Current Biology
December 9, 2025
Sarah G. Cook, Stephanie J. Lee, Emma Ference et al.
3 citations
Following decades of prohibition, psychedelic drugs have reemerged as promising therapeutics for stress-related conditions, including depression and post-traumatic stress disorder. Still, their impact on stress-related brain regions and the hypothalamic-pituitary-adrenal (HPA) axis remains unclear. This work explores the acute effects of psilocybin on the primary regulators of the HPA axis:...
Journal of Medicinal Chemistry
November 20, 2023
Kaveh Matinkhoo, Lisa Yu, David Press et al.
18 citations
The psychedelic prodrug psilocybin has shown therapeutic benefits for the treatment of numerous psychiatric conditions. Despite positive clinical end points targeting depression and anxiety, concerns regarding the duration of the psychedelic experience produced by psilocybin, associated with enduring systemic exposure to the active metabolite psilocin, pose a barrier to its therapeutic...
Research Square
March 10, 2023
Xue Chen, Jing Li, Lisa Yu et al.
Abstract Psychedelic indolethylamines have emerged as potential medicines to treat several psychiatric pathologies. Natural sources of these compounds include ‘magic mushrooms’, plants used to prepare ahayuasca, and toads. Owing to the occurrence of indolethylamines such as N,N-dimethyltryptamine, toad skin and parotid gland preparations have a history of ceremonial use, yet their biosynthesis...
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
August 2007
Sheila N Garland, Linda E Carlson, Sarah Cook et al.
The aim of this study was to compare a mindfulness-based stress reduction (MBSR) program and a healing through the creative arts (HA) program on measures of post-traumatic growth (PTGI-R), spirituality (FACIT-Sp), stress (SOSI), and mood disturbance (POMS) in cancer patients. A sample of cancer outpatients (MBSR, n = 60; HA, n = 44) with a variety of diagnoses chose to attend either an 8-week...